Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1300636 | 0.88 | RAB9A (0.46) | PYGLKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL1316455 | 0.84 | MMP13 (0.47) | PYGLRAB9ANPC1MMP13 | |
| SCHEMBL1317535 | 0.83 | MAPT (0.54) | MEN1ALDH1A1KMT2AMAPTRAB9A | |
| SCHEMBL1300144 | 0.83 | PYGL (0.47) | PYGL | |
| SCHEMBL1300152 | 0.83 | PYGL (0.48) | PYGLKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL1317254 | 0.82 | MCHR1 (0.44) | PYGLKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL1299819 | 0.81 | PYGL (0.44) | PYGL | |
| SCHEMBL1299840 | 0.80 | PYGL (0.54) | PYGL | |
| SCHEMBL1300606 | 0.79 | PYGL (0.53) | PYGL | |
| SCHEMBL1299827 | 0.79 | PYGL (0.55) | PYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269668-A1 | Fused Heteroaryl Diamide Compounds Useful as MMP-13 Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| EP-2344480-A1 | FUSED HETEROARYL DIAMIDE COMPOUNDS USEFUL AS MMP-13 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2011-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269668-A1 | Fused Heteroaryl Diamide Compounds Useful as MMP-13 Inhibitors | MMP13, MMP2, MMP3 | PYGL 2628/4885KDM4E 2482/4885MEN1 2025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.